Navigation Links
Veteran International Health Care Executive Appointed CEO of BeneChill(R)

SAN DIEGO and STOCKHOLM, June 4 /PRNewswire/ -- Amgen executive Alan Raffensperger has been appointed the new Chief Executive Officer of BeneChill, a privately held medical device company launching its first product, a novel cooling device for use by emergency response teams in the field, later this year in Europe.  With more than 25 years of experience in the pharmaceutical, biotechnology, medical device and diagnostic industries, Mr. Raffensperger joins BeneChill from his post as Executive Director and Franchise Head of Nephrology for Amgen, a global biopharmaceutical company.  He joined Amgen in 2005 as General Manager of the Nordic and Baltic Region, overseeing operations in eight countries from his Sweden base.



"As we prepare to launch our lead RhinoChill™ product in Europe, it was critical that we recruit a seasoned, well-rounded CEO with big pharma experience and the sensitivity to a smaller company," said Denise Barbut, M.D., Executive Chair and founder of BeneChill. "Alan's stellar track record and experience in product development, sales and marketing will enable us to achieve our business goals."

Prior to Amgen, Mr. Raffensperger was with Hoffman La Roche for ten years with his most recent position as Head of Pharmaceutical Marketing and Sales for Roche in Sweden. Previously, he was the CEO for Swedemed, a privately-held developer of an advanced ultrasonic surgery system. He began his career with Pharmacia, first in sales in the U.S. and then product management in Sweden.

Earlier in his career, Mr. Raffensperger was a paramedic for National Hospital in Arlington, VA and notes that his experience in cardiovascular and trauma emergency care provides a solid foundation for understanding the need for BeneChill's cooling devices in the field.  He received his Bachelor of Science degree in Emergency Health Sciences Management from the University of Maryland and was an MBA candidate at George Washington University.  He is a nationally registered EMT-paramedic.

BeneChill® is a privately held medical device company that develops novel, rapid cooling systems to improve survival after cardiac arrest.  RhinoChill™ can be administered quickly and directly to the brain by a proprietary portable system that uses a nasal catheter to deliver a rapid evaporative coolant and will be marketed in Europe later this year. With corporate headquarters in San Diego, CA, BeneChill will be opening offices in Switzerland.  

SOURCE BeneChill
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. American Legion Anticipates Institute of Medicine Report on Gulf War Veterans
2. Large, Long-Term Veterans Affairs Diabetes Trial (VADT) Reveals Important Cardiovascular Safety News on AVANDIA(R)
3. MultiVu Video Feed: Large, Long-Term Veterans Affairs Diabetes Trial (VADT) Reveals Important Cardiovascular Safety News on AVANDIA
4. Secretary Reinforces VAs Commitment to Research Safety and Veteran Focus
5. Enobia Pharma Appoints Industry Veterans with Commercial and Manufacturing Expertise to Expand Senior Management Team
6. Congresswoman Supporting Spinal Cord Research Intended to Benefit U.S. Veterans
7. NovaRx Appoints Industry Veteran as President and COO
8. For Iraq Veterans, Headaches Continue After Traumatic Brain Injury
9. Algos Attracts CRO Veteran Dr. Ganesh Iyer as its New CEO
10. Biotechnology Salutes Americas Veterans; Innovations Continue to Offer Improved Treatment and Care of Combat Troops
11. FREE Drug Discount Card Saves Money on Prescriptions and Raises Funds for Americas Disabled Veterans
Post Your Comments:
(Date:6/24/2016)... and SAN CLEMENTE, Calif. , June ... -based mobile pulmonary function testing company, is now able to ... devices developed by ndd Medical Technologies , Inc. ... done in hospital-based labs.  Thanks to ndd,s EasyOne PRO ® , ... , can get any needed testing done in the comfort of ...
(Date:6/24/2016)... 2016  Arkis BioSciences, a leading innovator in ... durable cerebrospinal fluid treatments, today announced it has ... is led by Innova Memphis, followed by Angel ... investors.  Arkis, new financing will accelerate the commercialization ... release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... 23, 2016  In a startling report released today, National ... by lacking a comprehensive, proven plan to eliminate prescription opioid overdoses. ... of how states are tackling the worst drug crisis in recorded ... – Kentucky , New Mexico ... . Of the 28 failing states, three – Michigan ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has dedicated ... has implemented orthobiologic procedures as a method for treating his patients. The procedure ... doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use to ...
(Date:6/24/2016)... ... ... Those who have experienced traumatic events may suffer from a complex set ... drug or alcohol abuse, as a coping mechanism. To avoid this pain and suffering, ... traumatic event. , Trauma sufferers tend to feel a range of emotions, from depression, ...
(Date:6/24/2016)... MIAMI, Fla. (PRWEB) , ... June 24, 2016 , ... ... Florida Trend magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this ... of Florida. , Seven Greenberg Traurig Shareholders received special honors as members of this ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... People across ... in Genome magazine’s Code Talker Award, an essay contest in which patients and their ... award to be presented at the 2016 National Society of Genetic Counselors (NSGC) Annual ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... actively feeding the Frederick area economy by obtaining investment capital for emerging technology ... past 2½ years that have already resulted in more than a million dollars ...
Breaking Medicine News(10 mins):